Loading

Pembrolizumab (Keytruda®)

Dokument Fact Sheet
Spezifizierung Lungenkarzinom, nicht-kleinzellig (NSCLC) » PD-L1 ≥1% » ab Zweitlinientherapie
Stand Juli 2021
Dies ist die aktuell gültige Version des Dokuments

1Pembrolizumab, NSCLC, PD-L1 ≥1%, second line

1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/414 results for control, results for new therapy15 hazard ratio for new therapy16 n. s. not significant29 Pemetrexed, Docetaxel or Nivolumab30 Pemetrexed, Docetaxel or Nivolumab

Kommentare